ClinicalTrials.govpublic full text
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
chronic lymphocytic leukemia (cll), small lymphocytic lymphoma (sll), phase ii, acalabrutinib, rituximab, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 895068
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.